KRAS and pancreatic neoplasm: To assess the hypothesis that the PARP inhibitor olaparib and TRAIL might exert a synergistic anticancer effect in pancreatic cancer cells, we selected three well-characterized PDAC cell lines with different driver mutation patterns: CAPAN1 (KRAS, CDKN2A, SMAD4, TP53), CAPAN2 (KRAS) [30] and PATU-S (KRAS, TP53, SMAD4) [31].